Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Steph & Co.

Steph & Co. reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 7,431 shares of the biopharmaceutical company’s stock after selling 212 shares during the quarter. Steph & Co.’s holdings in Gilead Sciences were worth $686,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of GILD. Avior Wealth Management LLC increased its holdings in shares of Gilead Sciences by 1.2% during the 3rd quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock worth $782,000 after buying an additional 108 shares during the last quarter. Concord Asset Management LLC VA raised its position in Gilead Sciences by 3.8% in the third quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock valued at $256,000 after purchasing an additional 111 shares during the period. TFB Advisors LLC raised its position in Gilead Sciences by 1.2% in the third quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock valued at $788,000 after purchasing an additional 116 shares during the period. Sumitomo Life Insurance Co. lifted its stake in shares of Gilead Sciences by 0.7% in the 3rd quarter. Sumitomo Life Insurance Co. now owns 17,822 shares of the biopharmaceutical company’s stock valued at $1,494,000 after purchasing an additional 117 shares during the last quarter. Finally, FDx Advisors Inc. increased its position in shares of Gilead Sciences by 2.2% during the 3rd quarter. FDx Advisors Inc. now owns 5,365 shares of the biopharmaceutical company’s stock worth $450,000 after purchasing an additional 117 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the sale, the director now directly owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 8,500 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $91.96, for a total value of $781,660.00. Following the transaction, the chief financial officer now directly owns 132,373 shares in the company, valued at approximately $12,173,021.08. This represents a 6.03 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 453,734 shares of company stock valued at $41,902,086. Insiders own 0.29% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Daiwa America raised shares of Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Cantor Fitzgerald restated a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a research note on Wednesday, December 11th. Morgan Stanley raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $87.00 to $113.00 in a research note on Friday, January 10th. Finally, UBS Group increased their target price on Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research note on Thursday, November 21st. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $97.96.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $92.38 on Thursday. The firm has a market capitalization of $115.13 billion, a PE ratio of 1,026.44, a price-to-earnings-growth ratio of 1.27 and a beta of 0.18. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The stock’s 50-day simple moving average is $91.96 and its 200-day simple moving average is $83.69.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. During the same quarter in the previous year, the firm earned $2.29 EPS. The company’s revenue was up 7.0% compared to the same quarter last year. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.33%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.